31 October 2022 : Clinical Research
hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis
Hanjiang Xu123BCDEF*, Meng Zhang123BCDEF, Zongyao Hao123AC, Chaozhao Liang123ADOI: 10.12659/MSM.938012
Med Sci Monit 2022; 28:e938012
Table 2 hOGG1 (rs1052133) gene polymorphism in patients with prostate cancer and controls.
| Parameter | Control N (%) | Case N (%) | OR (95% CI) | P-value |
|---|---|---|---|---|
| C/C | 40 (16.46) | 20 (12.50) | 1 (Ref.) | |
| C/G | 109 (44.86) | 85 (53.13) | 1.56 (0.86, 2.90) | 0.151 |
| G/G | 94 (38.68) | 55 (34.37) | 1.17 (0.63, 2.23) | 0.626 |
| C/G+G/G | 203 (83.54) | 140 (87.50) | 1.38 (0.78, 2.50) | 0.276 |
| C allele | 189 (38.89) | 125 (39.06) | 1 (Ref.) | |
| G allele | 297 (61.11) | 195 (60.94) | 0.99 (0.74, 1.33) | 0.961 |
| N – number; Ref. – reference. | ||||